Analyst Research

Report Title Price
Provider: Stock Traders Daily
$20.00
Provider: MacroRisk Analytics/EconomicInvestor
$25.00
Provider: ValuEngine, Inc.
$25.00
Provider: S&P Capital IQ – STARS Reports
$127.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Novartis AG Announces Divestiture Of Blood Transfusion Diagnostics Unit To Grifols SA


Monday, 11 Nov 2013 01:05am EST 

Novartis AG announced a definitive agreement to divest its blood transfusion diagnostics unit to Grifols SA for USD1.675 billion. This transaction, requiring customary regulatory approvals, is expected to be completed in the first half of 2014. Acquired in 2006 as part of Chiron, the blood transfusion diagnostics unit has formed part of Novartis Vaccines and Diagnostics. Not included in the sale is the Novartis companion diagnostics unit that is integrated into the pharmaceuticals business, nor the Genoptix business, as these fare closely linked to the pharmaceuticals pipeline. 

Company Quote

81.1
0.25 +0.31%
4:00am EDT